BioNTech Results Presentation Deck

BNT162 Commercial update 22 Pfizer FOSUNPHARMA 复星医药 Co-development and Co-commercialization worldwide (ex China) if approved Combined upfront payment and equity investment of $185 million to BioN Tech received in April Capital expenditures to be funded by each party independently Companies to share development expenses and gross profits on a 50:50 basis • BioNTech eligible to receive further development & sales milestones up to $563 million. ● ● ● ● Co-development with Fosun Pharma to hold exclusive marketing rights in China if approved • Combined upfront payment and equity investment of $51 million to BioNTech received in April ● Fosun Pharma to fund development expenses in China • BioNTech and Fosun to share gross profits on the sale of the vaccine in China BioN Tech eligible to receive further China development & sales milestones up to $84 million ● ● BIONTECH

View entire presentation